KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunothe...
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
About this item
Full title
Author / Creator
Liu, Chengming , Zheng, Sufei , Wang, Zhanyu , Wang, Sihui , Wang, Xinfeng , Yang, Lu , Xu, Haiyan , Cao, Zheng , Feng, Xiaoli , Xue, Qi , Wang, Yan , Sun, Nan and He, Jie
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Although immune checkpoint inhibitors (ICIs) against programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients with non‐small cell lung carcinoma (NSCLC), the potential association between Kirsten rat sarcoma viral oncogene homolog (KRAS) oncogene substitutions and the efficacy of...
Alternative Titles
Full title
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b8bb7a9a6c6a46f98594887e66e97fbe
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b8bb7a9a6c6a46f98594887e66e97fbe
Other Identifiers
ISSN
2523-3548
E-ISSN
2523-3548
DOI
10.1002/cac2.12327
